The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. (Q34613443)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

review article

1 reference

title

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S P R Romaine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

K M Bailey

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A J Balmforth

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

3 November 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

The Pharmacogenomics Journal

11 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

1-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19884908%20AND%20SRC:MED&resulttype=core&format=json

Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Clinical implications of pharmacogenomics of statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Narrative review: statin-related myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Statin safety: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Molecular basis of statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Role of OATP transporters in the disposition of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Role of P-glycoprotein in statin drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Global analysis of genetic variation in SLCO1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

An association study of 43 SNPs in 16 candidate genes with atorvastatin response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54

SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2009.54